Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice.

@article{Gholizadeh2007UltralowDC,
  title={Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice.},
  author={Shervin Gholizadeh and Hamed Shafaroodi and Mehdi Keshavarz Ghasemi and Arash Bahremand and Mohammad Sharifzadeh and Ahmad Reza Dehpour},
  journal={Neuropharmacology},
  year={2007},
  volume={53 6},
  pages={763-70}
}
Several lines of evidence suggest that cannabinoid compounds are anticonvulsant since they have inhibitory effects at micromolar doses, which are mediated by activated receptors coupling to Gi/o proteins. Surprisingly, both the analgesic and anticonvulsant effects of opioids are enhanced by ultra-low doses (nanomolar to picomolar) of the opioid antagonist naltrexone and as opioid and cannabinoid systems interact, it has been shown that ultra-low dose naltrexone also enhances cannabinoid-induced… CONTINUE READING